Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Other Non-Current Liabilities (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $132000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed N/A to $132000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $132000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $132000.0 for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities hit $132000.0 in Q4 2025 for Bolt Biotherapeutics, down from $133000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $321000.0 in Q1 2021 to a low of $42000.0 in Q4 2022.
  • Historically, Other Non-Current Liabilities has averaged $145562.5 across 4 years, with a median of $133000.0 in 2025.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 80.0% in 2022 and later grew 2.38% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $210000.0 in 2021, then plummeted by 80.0% to $42000.0 in 2022, then increased by 2.38% to $43000.0 in 2023, then soared by 206.98% to $132000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for BOLT at $132000.0 in Q4 2025, $133000.0 in Q3 2025, and $133000.0 in Q2 2025.